Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study

BACKGROUND: The objective of our study was to conduct a cost-effectiveness (CE) study of combined everolimus (EVE) and exemestane (EXE) versus the common clinical practice in Greece for the treatment of postmenopausal women with HR+/HER2- advanced breast cancer (BC) progressing on nonsteroidal aroma...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Health Serv Res
Auteurs principaux: Kourlaba, Georgia, Rapti, Vasiliki, Alexopoulos, Athanasios, Relakis, John, Koumakis, Georgios, Chatzikou, Magdalini, Maniadakis, Nikos, Georgoulias, Vassilis
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2015
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4524048/
https://ncbi.nlm.nih.gov/pubmed/26239115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12913-015-0971-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires